Twist Bioscience Corporation has defied expectations with its impressive financial performance in the third quarter, marking a significant shift from previous losses to profits within a year. This turnaround was highlighted by the company’s reported third-quarter income of 33 cents per share, a stark improvement from a loss of $1.47 per share a year earlier, significantly outperforming analysts’ projections.
The notable financial results for Twist Bioscience in Q3 included a net income of $20.39 million, which encompassed a gain of $48.85 million from the sale of part of the business, equivalent to 80 cents per share. Excluding this gain, the adjusted loss stood at 47 cents per share. Moreover, the company’s sales for the quarter reached $96.057 million, surpassing both the previous year’s figures and the consensus estimate, falling within the management’s guidance range.
During the third quarter of fiscal 2025, Twist Bioscience saw an increase in product shipments to approximately 2,484 customers, up from around 2,300 customers in the same period last year. Notably, the company shipped approximately 237,000 genes, reflecting growth compared to the previous year. The gross margin for the quarter also saw a significant boost, rising to 53.4% from 43.3% year-on-year.
In terms of financial guidance, Twist Bioscience narrowed its fiscal year 2025 sales forecast to $374 million-$376 million, with the breakdown including revenue projections for SynBio, NGS, and Biopharma segments. The company anticipates achieving adjusted EBITDA breakeven by the conclusion of fiscal 2026, showcasing a commitment to sustained financial growth and stability.
Looking ahead, the company expects fourth-quarter 2025 sales to range between $96 million and $98 million, with corresponding revenue projections for its various segments. Twist Bioscience aims for a gross margin of 51%-52% in Q4 and projects adjusted EBITDA to fall within the range of $(6.0) million to $(8.0) million. Despite a recent decline in stock value, the company remains focused on its strategic financial goals and maintaining a trajectory towards profitability.
Key Takeaways:
– Twist Bioscience’s third-quarter performance exceeded expectations, with notable increases in sales and profitability.
– The company’s strategic focus on key segments like SynBio, NGS, and Biopharma is reflected in its revised sales guidance for fiscal year 2025.
– Twist Bioscience aims to achieve adjusted EBITDA breakeven by the end of fiscal 2026, underlining its commitment to long-term financial stability and growth.
– Despite short-term stock value fluctuations, the company’s strong financial fundamentals and strategic direction position it for continued success in the biotech industry.
Read more on benzinga.com